{"filing":{"accession_number":"0001213900-26-111852","cik":"0001611746","ticker":"SPRC","company_name":"SciSparc Ltd.","form":"6-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"ea0309410-6k_scisparc.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611746/000121390026111852/ea0309410-6k_scisparc.htm"},"events":[{"id":37416,"run_id":34489,"accession_number":"0001213900-26-111852","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces a significant operational and clinical milestone for SciSparc's subsidiary NeuroThera: successful completion of manufacturing and European QP batch release certification for SCI-110, completion of site initiation activities across three clinical centers, and advancement toward patient enrollment in an FDA-approved Phase IIb clinical trial for Tourette Syndrome. While this is a positive development in an ongoing drug development program rather than a discrete financial event, M\u0026A activity, or executive change, it represents material progress in a key clinical program that would affect a reasonable investor's assessment of the company's pipeline advancement and near-term operational trajectory.","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-10-23","form":"6-K","submitted_at":null,"items":[{"id":42122,"accession_number":"0001213900-26-111852","item_number":"EX-99.1","item_title":"ea030941001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a significant operational and clinical milestone for SciSparc's subsidiary NeuroThera: successful completion of manufacturing and European QP batch release certification for SCI-110, completion of site initiation activities across three clinical centers, and advancement toward patient enrollment in an FDA-approved Phase IIb clinical trial for Tourette Syndrome. While this is a positive development in an ongoing drug development program rather than a discrete financial event, M\u0026A activity, or executive change, it represents material progress in a key clinical program that would affect a reasonable investor's assessment of the company's pipeline advancement and near-term operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T11:00:42.080887+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42122,"accession_number":"0001213900-26-111852","item_number":"EX-99.1","item_title":"ea030941001ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a significant operational and clinical milestone for SciSparc's subsidiary NeuroThera: successful completion of manufacturing and European QP batch release certification for SCI-110, completion of site initiation activities across three clinical centers, and advancement toward patient enrollment in an FDA-approved Phase IIb clinical trial for Tourette Syndrome. While this is a positive development in an ongoing drug development program rather than a discrete financial event, M\u0026A activity, or executive change, it represents material progress in a key clinical program that would affect a reasonable investor's assessment of the company's pipeline advancement and near-term operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T11:00:42.080887+00:00","company_name":"SciSparc Ltd.","ticker":"SPRC","filing_date":"2026-10-23"}]}